Abstract
Severe COVID-19 disease is currently being managed with glucocorticoids. As a result, there are increasing reports of COVID-19 associated mucormycosis. (CAM) Patients with diabetes mellitus, organ transplant recipients, and in immune-compromised patients either due to cancer chemotherapy or with HIV and AIDS are at high risk of developing CAM. Pharmacotherapy with antifungal agents like Amphotericin B and surgery are the main treatment options. In this narrative review, we will discuss the challenges and anesthetic concern while managing CAM.
Keywords
References
-
1.
References are in the PDF file of the article.
Copyright
© 2021, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.